Table 6.
Summary of the Euroimmun, InBios, and Abcam CHIK MAC-ELISAs and Euroimmun IIFT evaluations at CARPHA, CDC, and NML
| Reference laboratory (no. of samples tested) | % Sensitivity (95% CI) | % Specificity (95% CI) | Accuracy (95% CI) |
|---|---|---|---|
| Abcam ELISA* | |||
| CDC (N = 68) | 100 (88–100) | 97 (82–100) | 99 (91–100) |
| Euroimmun ELISA | |||
| CARPHA (N = 36) | 100 (84–100) | 100 (66–100) | 100 (88–100) |
| CDC (N = 68) | 100 (88–100) | 97 (82–100) | 99 (91–100) |
| NML (N = 247) | 94 (87–98) | 96 (91–98) | 95 (91–97) |
| Euroimmun IIFT | |||
| CARPHA (N = 33) | 100 (81–100) | 92 (60–100) | 97 (82–100) |
| CDC (N = 75) | 92 (77–98) | 100 (89–100) | 96 (88–99) |
| InBios ELISA | |||
| CARPHA (N = 41) | 100 (84–100) | 93 (64–100) | 98 (86–100) |
| CDC (N = 68) | 100 (88–100) | 100 (87–100) | 100 (93–100) |
CARPHA = Caribbean Public Health Agency; CDC = Centers for Disease Control and Prevention; CHIK = chikungunya; CI = confidence interval; IIFT = indirect immunofluorescent test; MAC-ELISA = IgM antibody-capture enzyme-linked immunosorbent assay; NML = the Public Health Agency of Canada National Microbiology Laboratory.
*
Revised kit. CARPHA evaluation of the Abcam kit not included, as the kit components were modified after the evaluation, invalidating the results.